Recombinant IDH1-R132G (Isocitrate Dehydrogenase) Antibody, Clone: [IDH1.R132G/13054R], Rabbit, Monoclonal
Catalog Number:
NBT-3417-RBM13-P1ABX
- Images (0)
| Article Name: | Recombinant IDH1-R132G (Isocitrate Dehydrogenase) Antibody, Clone: [IDH1.R132G/13054R], Rabbit, Monoclonal |
| Biozol Catalog Number: | NBT-3417-RBM13-P1ABX |
| Supplier Catalog Number: | 3417-RBM13-P1ABX |
| Alternative Catalog Number: | NBT-3417-RBM13-P1ABX-100 |
| Manufacturer: | NeoBiotechnologies |
| Host: | Rabbit |
| Category: | Antikörper |
| Application: | IHC |
| Species Reactivity: | Human |
| Immunogen: | Recombinant fragment of human IDH1 protein with R132G (exact sequence is proprietary) |
| Alternative Names: | Cytosolic NADP-isocitrate dehydrogenase, Epididymis luminal protein 216, Epididymis secretory protein Li 26, HEL-216, HEL-S-26, ICDH, IDCD, IDH1, IDP, IDPC, Isocitrate dehydrogenase 1 (NADP+) soluble, NADP dependent isocitrate dehydrogenase peroxisomal, NADP(+)-specific ICDH, Oxalosuccinate decarboxylase, PICD |
| The gene represented in this entry is involved in disease pathogenesis. Mutations affecting Arg-132 are tissue-specific, and suggest that this residue plays a unique role in the development of high-grade gliomas. Mutations of Arg-132 to Cys, His, Leu or Ser abolish magnesium binding and abolish the conversion of isocitrate to alpha-ketoglutarate. Instead, alpha-ketoglutarate is converted to R(-)-2-hydroxyglutarate. Elevated levels of R(-)-2-hydroxyglutarate are correlated with an elevated risk of malignant brain tumors. Genetic variations are associated with cartilaginous tumors such as enchondroma or chondrosarcoma. Mutations of Arg-132 to Cys, Gly or His abolish the conversion of isocitrate to alpha-ketoglutarate. Instead, alpha-ketoglutarate is converted to R(-)-2-hydroxyglutarate. |
Product Guarantee and Expert Support
